Marco Lionello
University of Padua
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Marco Lionello.
Histopathology | 2010
Gino Marioni; Filippo Marino; Stella Blandamura; Emiliano D’Alessandro; Luciano Giacomelli; Vincenza Guzzardo; Marco Lionello; Cosimo De Filippis; Alberto Staffieri
Marioni G, Marino F, Blandamura S, D’Alessandro E, Giacomelli L, Guzzardo V, Lionello M, de Filippis C & Staffieri A (2010) Histopathology57, 535–543 Neoangiogenesis in laryngeal carcinoma: angiogenin and CD105 expression is related to carcinoma recurrence rate and disease‐free survival
Laryngoscope | 2014
Elisabetta Zanoletti; Gino Marioni; Paola Stritoni; Marco Lionello; Luciano Giacomelli; Alessandro Martini; Antonio Mazzoni
Temporal bone squamous cell carcinoma (SCC) is an uncommon malignancy accounting for less than 0.2% of head and neck cancers. Despite advances in its early diagnosis, skull base microsurgery, radiotherapy, and integrated treatments, prognosis in advanced SCCs remains dismal. The present study aimed to analyze the clinicopathological variables potentially influencing outcome in a series of temporal bone SCCs.
Acta Oto-laryngologica | 2012
Marco Lionello; Alberto Staffieri; Gino Marioni
Abstract Angiogenesis is a hallmark of cancer, fundamental to its growth. The ‘angiogenic switch’ occurs when pro-angiogenic factors are not balanced by anti-angiogenic factors. A correlation between angiogenic properties and oncological prognosis (for laryngeal squamous cell carcinoma (LSCC) too) was first hypothesized in the 1990s. An exhaustive literature review was performed to investigate available data on angiogenesis markers and their biological role and therapeutic potential in LSCC. The prognostic significance of microvascular density in LSCC was investigated with endothelial targets, e.g. CD105, CD34, and CD31. Epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), VEGF receptor 2, angiogenin, hypoxia-inducible factor 1, and other biological markers were also studied. Only anti-EGFR therapy has been approved by the USFood and Drug Administration (FDA) for head and neck carcinoma in recent years, while several agents interfering with VEGF and its receptors are being studied. Experimental findings indicate that anti-CD105 monoclonal antibodies efficiently inhibit tumor angiogenesis. There are two main ways to approach the vascular profile of solid malignancies: by inhibiting new vessel formation (anti-angiogenic therapy) or selectively damaging neoplastic vessels (vascular targeting therapy). In advanced LSCC, both these strategies seem promising and warrant further preclinical and clinical investigation.
Histopathology | 2012
Gino Marioni; Marco Agostini; Chiara Bedin; Stella Blandamura; Edoardo Stellini; Giovanni Favero; Marco Lionello; Luciano Giacomelli; Silvia Burti; Edoardo D’Angelo; Donato Nitti; Alberto Staffieri; Cosimo De Filippis
Marioni G, Agostini M, Bedin C, Blandamura S, Stellini E, Favero G, Lionello M, Giacomelli L, Burti S, D’Angelo E, Nitti D, Staffieri A & De Filippis C (2012) Histopathology 61, 247–256
Head and Neck-journal for The Sciences and Specialties of The Head and Neck | 2014
Gino Marioni; Stella Blandamura; Marco Lionello; Luciano Giacomelli; Andrea Lovato; Niccolò Favaretto; Stefano Breda; Giulia Tealdo; Vincenza Guzzardo; Giancarlo Ottaviano; Alberto Staffieri
Combining primary surgery with postoperative radiotherapy (RT) significantly reduces locoregional recurrence rates in selected patients with laryngeal squamous cell carcinoma (SCC). A prognostic model was used to see if associating laryngeal SCC tissue markers (mammary serine protease inhibitor [MASPIN], CD105, angiogenin [ANG], and nm23‐H1) with conventional criteria could better discriminate higher‐risk patients warranting postoperative RT.
Archives of Otolaryngology-head & Neck Surgery | 2011
Gino Marioni; Alberto Staffieri; Enzo Manzato; Giovanni Ralli; Marco Lionello; Luciano Giacomelli; Vlatko Prosenikliev; Rosario Marchese-Ragona; Alessandra Busnardo; Francesco Bolzetta; Stella Blandamura
OBJECTIVES To ascertain the prognostic role of endoglin (CD105)-assessed microvessel density (MVD) in patients older than 65 years with laryngeal squamous cell carcinoma (LSCC), and whether this MVD differed in the elderly patients from younger adult controls. DESIGN Retrospective clinicopathologic investigation. SETTING Academic tertiary referral center. PATIENTS Fifty-seven consecutive elderly patients with LSCC and 19 younger adult controls. MAIN OUTCOME MEASURE Image analysis of immunohistochemical reactions. RESULTS In LSCCs in elderly patients, N+ stage correlated with a shorter disease-free survival (DFS) (P < .001). A higher CD105-assessed MVD was associated with disease recurrence (P = .006). The DFS was shorter in elderly patients whose CD105 expression was greater than 9.6% than in patients whose CD105 expression was 9.6% or less (P = .001). Among the elderly patients with tumors staged as N0, a higher CD105-assessed MVD correlated with disease recurrence (P = .006) and a shorter DFS (P = .001). CD105-assessed MVD in LSCC occurring in elderly patients did not differ from the situation observed in younger adult controls (P = .74). CONCLUSIONS In LSCC occurring in elderly patients, CD105-assessed MVD may be a useful N-stage independent, angiogenic prognostic marker for pinpointing: (1) patients at higher risk of disease recurrence; and (2) patients with N0 tumors at higher risk of early recurrence, who may benefit from more aggressive therapy.
Histopathology | 2013
Gino Marioni; Elisabetta Zanoletti; Paola Stritoni; Marco Lionello; Luciano Giacomelli; Andrea Gianatti; Laura Cattaneo; Stella Blandamura; Antonio Mazzoni; Alessandro Martini
Although it accounts for fewer than 0.2% of all head and neck tumours, temporal bone squamous cell carcinoma (SCC) is an aggressive malignancy with a poor prognosis in advanced cases. Novel therapeutic strategies should be developed focusing on specific targeted therapies. Maspin is a serpin showing tumour‐suppressing activity which has therapeutic potential. The present study is the first to investigate maspin expression in temporal bone SCCs, using a series of 29 cases.
Histopathology | 2012
Gino Marioni; Giancarlo Ottaviano; Marco Lionello; Lucia Lora; Andrea Lovato; Claudia Staffieri; Niccolò Favaretto; Luciano Giacomelli; Edoardo Stellini; Alberto Staffieri; Stella Blandamura
Marioni G, Ottaviano G, Lionello M, Lora L, Lovato A, Staffieri C, Favaretto N, Giacomelli L, Stellini E, Staffieri A & Blandamura S (2012) Histopathology Nm23‐H1 nuclear expression is associated with a more favourable prognosis in laryngeal carcinoma: univariate and multivariate analysis
Acta Oto-laryngologica | 2011
Gino Marioni; Stella Blandamura; Marco Lionello; Luciano Giacomelli; Claudia Staffieri; Elena Fasanaro; Enzo Manzato; Alberto Staffieri
Abstract Conclusion: MASPIN subcellular location can be considered a prognostic marker that is potentially useful for identifying elderly patients with laryngeal carcinoma at higher risk of early loco-regional recurrence, who may benefit from more aggressive therapy. In a targeted treatment setting, re-activated nuclear MASPIN in combination with anti-angiogenic and/or cytotoxic drugs may be effective in treating laryngeal carcinoma in elderly patients. Objectives: Aging is associated with molecular, cellular, and physiological changes that influence carcinogenesis and cancer growth. MASPIN has multifaceted anti-tumor effects and available evidence supports the hypothesis that its subcellular location influences its functions. The aim of the present study was to firstly assess the potential prognostic role of subcellular MASPIN location in elderly patients (>65 years old) with laryngeal carcinoma. Methods: MASPIN expression and location were immunohistochemically determined in 68 consecutive elderly patients with laryngeal carcinoma. Results: Nodal involvement and pathological stage correlated strongly with the prognosis for laryngeal carcinomas in elderly patients, in terms of disease recurrence rate and disease-free survival. The loco-regional recurrence rate was significantly lower (p = 0.041) and the disease-free survival after treatment was significantly longer (p = 0.045) in cases with a nuclear pattern of MASPIN subcellular expression.
Laryngoscope | 2013
Rosario Marchese-Ragona; Andrea Vianello; Domenico A. Restivo; Giovanni Pittoni; Marco Lionello; Alessandro Martini; Daniele Manfredini; Bhik Kotecha; Alberto Staffieri
Obstructive sleep apnea syndrome (OSAS) is a chronic condition, characterized by recurrent episodes of upper airway collapse during sleep, which affects up to 5% of adults in the Western population. The muscle tone of the human body ordinarily relaxes during sleep, thus causing airway obstruction and leading to sleep apnea. We report a case of a 68‐years old male in which dystonic closure of the larynx during sleep caused OSAS. The sleep endoscopy was crucial in establishing the diagnosis of laryngeal dystonia. A botulinum toxin injection in the vocal cord improved the OSAS. These findings define a novel sleep‐related breathing disorder.